Avenue Therapeutics (ATXI)
(Delayed Data from NSDQ)
$2.12 USD
+0.03 (1.44%)
Updated Oct 16, 2024 03:58 PM ET
After-Market: $2.13 +0.01 (0.47%) 5:42 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ATXI 2.12 +0.03(1.44%)
Will ATXI be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ATXI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for ATXI
Allarity appoints Alex Epshinsky as CFO
Avenue Therapeutics to Participate in Upcoming Investor Conferences
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics: A Strong Buy on Promising AJ201 Developments and Strategic Initiatives